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Abstract
Medication Non-Compliance: Compliance to Psychotropic Medications within
Community Mental Health
by
Emily DePetro, M.S.
Committee Chair: Patrick J. Aragon, Psy.D.

According to the American Psychological Association (2019),
approximately 25% of the adult US population has a mental illness. The cost to
individuals as well as the United States government is significant, as it has been
found that approximately 100-300 billion dollars spent annually are attributed to
medication non-compliance (Iuga & McGuire, 2014). There has been significant
research completed with regards to medication non-compliance within specific
populations including individuals afflicted with Schizophrenia and Bipolar
Disorder. However, there is a significant gap in the literature regarding
psychotropic medication non-compliance in the general mental health outpatient
population, as well as with regards to the barriers to compliance with psychotropic
medication.
The present study sought to identify which factors including: Forgetting,
Adverse Side Effects, Financial Reasons, Religious Reasons, History of Addiction,
Unsure if Medications are Working, and Inconvenience: significantly increase
iii

medication non-compliance in the general outpatient mental health population. The
survey utilized in this study was used to identify medication non-compliance and
its factors within the local population. The survey was disseminated to two local
community mental health outpatient clinics and participants (n=195) were asked to
provide information regarding medication compliance behaviors. Results of the
study found that no individual factor significantly predicted medication noncompliance F (8,89) = .90, p= .52.
Adverse Side Effects and Forgetting, on the other hand, were found to be
more likely than other factors to predict the non-compliance. It was also found that
Adverse Side Effects were found to be significantly more likely to result in the
individual terminating their medication usage without first consulting their
medication provider F (8,63) = 3.46, p<.002, with an R2 of 0.31. Contrary to the
hypothesis, no significant difference was found between individuals’ medication
non-compliance and the inclusion of a prescribed antipsychotic medication (M =
0.63, SD= 0.49; M=0.5, SD = 0.58). Despite inconsistent results, it is noted that
Adverse Side Effects is recognized as a factor that is significantly likely to
influence individuals terminating their medication usage without consulting their
provider. It is also beneficial to acknowledge that Forgetting and Adverse Side
Effects are likely to be target factors for preventative action to be taken by
medication providers. Future studies may add to this literature by examining the
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efficacy of preventative measures on medication non-compliance factors such as
Forgetting and Adverse Side Effects.
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Medication Non-Compliance: Compliance to Psychotropic Medications within
Community Mental Health
The American Psychological Association reported that approximately one
in four, or 25% of U.S. adults have a mental illness. It was further reported that
nearly 50% of U.S. adults will develop a mental illness within their lifetime
(American Psychological Association, 2019). Of those suffering, less than half, or
19.2 million individuals received mental health treatment, which consists of either
inpatient or outpatient treatment/counseling, and/or the use of prescribed
psychotropic medication (NAMI, 2017). Medication non-compliance amongst
mental health patients, especially those with serious mental illness such as
schizophrenia, is the most frequent reason for rehospitalization in a mental health
facility (Sullivan, Wells, Morgenstern, & Leake, 1995). Between 100-300 billion
dollars of avoidable healthcare costs have been attributed to medication noncompliance in the United States annually (Iuga & McGuire, 2014). Avoidable costs
include such things as misplaced resources, unemployment, absence from work,
and premature mortality are associated with medication non-compliance in mental
health patients (Semahegn et al., 2018). In fact, approximately 26% of homeless
adults staying in shelters are living with a serious mental illness (Khadduri &
Culhane, 2011). It has also been found that approximately 20% of state prisoners
and 21% of local jail prisoners have a history of a mental health condition (Glaze &
James, 2006). A startling statistic indicates that more than 90% of individuals who
1

die by suicide show symptomatology of a mental health condition (Isometsa, 2001).
This is even more concerning when recognizing that the National Institute of
Mental Health (NIMH; NIMH, 2019) stated in 2018 that suicide is the 10th leading
cause of death in the U.S., and it is the 2nd leading cause of death for individuals
who are between the ages of 10-34. This significant impact of mental health
problems in the U.S. can be mitigated through the use of medication and mental
health treatment compliance.
Psychotropic Medication Non-Compliance
Research has shown that the clinical non-attendance rate in mental health
treatment is twice that which is seen in most other medical specialties (Adeponle,
Baduku, Adelekan, Suleiman, & Adayemi, 2009). This is disturbing, when
considering that individuals who attend their mental health appointments are found
to be significantly more likely to comply with their psychotropic medications, than
those who do not or do so inconsistently (Joe & Lee, 2016). It has been also found
that individuals diagnosed with major psychiatric disorders tend to be the most
non-compliant with their psychotropic medication. One suspected cause of this is
that individuals who suffer from major psychiatric disorders tend to have impaired
reasoning skills and insight (Semahegn, et al., 2018).
A combination of psychotropic medication and psychotherapy is the most
efficacious form of treatment for mental health problems; however, there is still
significant concern with the lack of medication compliance amongst mental health
2

patients. It has been estimated that after a period of six months, more than 50% of
individuals diagnosed with a chronic illness do not take their medication as
prescribed (World Health Organization, 2003). For psychotropic medication to
provide the individual with the greatest benefit, the individual needs to take the
medication at the correct time, for the prescribed amount, and complete the full
course of medication treatment (Chapman & Horne, 2013). If the individual is not
taking their medication as prescribed and does not adequately report this to their
prescribing physician, the physician is then likely to prescribe unnecessary
increases in medication dosage, changes within the patient’s medication, addition
of supplementary medication, or the mistaken labeling of the patient as being
“treatment resistant” (Velligan et al., 2003). For instance, research has found that
only 67% of individuals diagnosed with Major Depressive Disorder achieve full
remission of symptoms after one year of treatment (Lam, 2011). However, what is
not included in that statistic is the compliance level of those individuals with their
medications.
When discussing compliance, it is important to understand the origin of the
word. Compliance was derived from the Latin word, complere, which means to
fulfill or complete an action or to fulfill a promise (Complere, n.d.). Therefore,
when one is medication compliant, it indicates that the individual is completing the
action of consuming their medication to continue the stated and expected treatment.
From the original definition of complere, it could also be interpreted that the patient
3

is fulfilling the promise to one’s medical provider to continue and complete the
prescribed treatment. However, for the purposes of this paper, medication
compliance will refer to an individual effectively fulfilling the action of medication
completion, as prescribed by one’s provider, including dosage amounts, frequency,
and duration. It should also be noted, throughout this paper, the terms compliance
and adherence will be used interchangeably.
Definition of medication non-compliance. A variety of different
operational definitions have been utilized for research dealing with psychotropic
medication non-compliance. These include: (a) failure to take any medication, (b)
taking a different dose than prescribed, and (c) premature termination of a
medication (Breen & Thornhill, 1998). Other studies have identified noncompliance as individuals taking only half or less than half of their prescribed
medications (Nageotte, Sullivan, Duan, & Camp, 1997), not taking medication as
prescribed (Bennet et al., 2013), having a pharmacy refill rate of 50% or less,
(Rosack, 2014) or a set of high risk behaviors with regard to taking medication
(Mahone, 2004).
Therefore, the following was considered to be most pertinent of the above
definitions; the premature termination of medications, taking half or less than half
of medications, not following dosage guidelines, and/or a set of high-risk behaviors
with regard to taking medication. As a result, the operational definition for
measuring psychotropic medication non- compliance from here forward will be: a
4

set of high-risk behaviors comprised of the following characteristics: not following
dosage guidelines, talking half or less than half of prescribed medication, or
choosing to prematurely terminate medication usage.
Diagnosis-Specific Medication Non-Compliance
Schizophrenia disorder. Patients diagnosed with schizophrenia is one of
the more widely researched disorders, in terms of medication compliance (Joe &
Lee, 2018). For example, a study based on former psychiatric inpatients from rural
Mississippi, comprised of all African- American males diagnosed with
schizophrenia found that out of 202 individuals, 47% were found to be noncompliant, with non-compliance measured as individuals who missed taking their
medication more than once or twice in the three-month period of the data collection
portion of the study. (Nageotte et al., 1997). These compliance data were gathered
not only through self-report, but also through their family members verifying the
validity of the report. The most salient reasoning for non-compliance for this
population was a disbelief/denial of having a mental illness, and not having
participated in outpatient care at the community mental health center for the past
three months (Nageotte et al., 1997).
In looking at the reasoning in which individuals with schizophrenia choose
to not comply with their medication regimes, there are multiple contributing factors
for consideration, including but not limited to: stigma, culture, and attitudes
towards medication. A study completed in India aimed to identify the relationship
5

between the attitudes towards medication and the reasons for non-compliance with
their medication used to treat their schizophrenia (Chandra, Kumar, Reddy, &
Reddy, 2014).). The researchers utilized a psychological instrument, the Positive
and Negative Symptoms Scale (PANSS) to assess the severity of the schizophrenia
in the participants (Chandra et al., 2014). Understanding of medication compliance
was assessed through the use of the 20-item Rating of Medical Influence scale
(ROMI). Analyzing the results of this data found that of 105 patients with
schizophrenia, 41.9% were found to be non-compliant with their medication. The
results of this study indicated that factors such as younger age, unemployment,
younger age at the onset of illness, and higher scores on the PANSS significantly
increased the likelihood of the occurrence of medication non-compliance (Chandra
et al., 2014).
Byerly et al. (2005) examined the accuracy of clinician rating antipsychotic
medication compliance in patients with schizophrenia through the use of an
electronic monitoring source of medication compliance. This study was comprised
of 25 adult participants that met the diagnostic category for schizophrenia or
schizoaffective disorder utilizing the Diagnostic and Statistical Manual of Mental
Disorders IV- Text Revision (DSM- IV- TR), and who were receiving outpatient
care from Dallas mental health clinics. Also incorporated in the inclusion criteria
was at least one hospitalization or psychiatric emergency room visit within the past
two years (Byerly et al., 2005). The subjects were given a Medical Event
6

Monitoring System (MEMS) cap for each of their prescribed antipsychotic
medications, and each time the medication bottle was opened, the monitoring
system produced a recorded date and time that would be printed out at the end of
the month. This data collection was a three-month period and non-compliance for
this study was declared when the individual was found to have opened the
medication bottle less than 70% of the prescribed medication times for each month.
During this assessment, the clinician would ask the participants information about
their medication compliance, and then rate each subject on the Clinician Rating
Scale, which is an ordinal scale of 1-7, with the higher numbers indicating stronger
compliance to medication. At the end of the three-month period, the MEMS data
and the Clinician Rating Scale data for each participant was obtained and recorded.
It was found that 48% of the subjects were found to be non-adherent to their
medication regime as recorded by the MEMS cap, whereas 0% of subjects were
found to be non-adherent by the clinician (Byerly et al., 2005). This study indicated
the likelihood of a significant overestimation of clinician’s ability to measure
medication compliance in their patients. This then leads to the question, why do
individuals continue to not adhere to their medication regimes?
Bipolar disorder. Individuals suffering from Bipolar Disorder often are
non-compliant with their prescribed medication regimes during the maintenance
treatment of their disorder (Li, Chen, Qiu, & Yang, 2014). It has been found that
approximately half of the individuals diagnosed with Bipolar Disorder are non7

compliant with long-term treatment with no significant distinction as to whether
they are prescribed mood stabilizers or antipsychotics (Chakrabarti, 2016). Bipolar
Disorder medication non-compliance is a salient issue, as suicide attempts occur in
25-50% of patients diagnosed with Bipolar Disorder (Berk et al., 2010). In fact,
Gonzalez-Pinto et al. (2006) found that patients who were non-adherent to their
medication, Lithium, were 5.2 times more likely to attempt and complete suicide
than those who were medication compliant.
Mood disorders, such as Major Depressive Disorder, Bipolar Disorder, and
Dysthymic Disorder have been found as the third most common cause of
hospitalization for U.S. individuals aged 18-44 years old (Agency for Healthcare
Research and Quality, 2009). Bipolar Disorder is often found to be comorbid with
substance abuse, anxiety disorders, and personality disorders. Furthermore,
significant non-compliance that occurs with individuals diagnosed with Bipolar
Disorder often results in skewed research of the efficacy of future treatments for
this disorder (Berk et al., 2010).
Rahmani, Ebrahimi, Ranjbar, Razavi, and Asghari (2016) reported that nine
out of ten individuals diagnosed with Bipolar Disorder think about quitting their
treatment, and at least one of these 10 individuals consider giving up mental health
treatment entirely during his/her lifetime. They also reported that at least 1 out of 3
individuals with Bipolar Disorder does not take more than 70% of the prescribed
medication, resulting in treatment failure, and an overall declining prognosis. As a
8

result of this information, a study was conducted by Rahmani et al., (2016) to
identify the efficacy of psychoeducation on medication compliance in Bipolar
Disorder individuals. This study was comprised of 72 individuals, ages 18-50, who
were diagnosed as suffering from Bipolar Disorder I. These individuals were then
placed either in the experimental group (n=38) or the control group (n=38). Those
in the experimental group received 10 continuous 90 minute sessions of
psychoeducation on medication compliance twice per week. Those in the control
group did not receive any psychoeducation. The results of the study indicated that
there was a significantly higher medication compliance level in those in the
experimental group in comparison with those in the control group (Rahmani et al.,
2016). Therefore, providing clients with psychoeducation with relation to both their
medications and their disorder proves to be more efficacious in their psychotropic
medication compliance.
Another study conducted by Li, Chen, Qiu, and Yang (2014), sought to
identify medication compliance and rehospitalization rates of 210 participants with
Bipolar Disorder, one and two years after their initial psychiatric hospital visits. It
was found that at one year post-discharge, 59% of the participants were considered
non-compliant with their medication. At two-years post-discharge, 64.3% of
participants were considered non-compliant. It was also found that the
reoccurrence, or rehospitalization rates at the one-year and two-year follow up
were, 42.4% and 61%, respectively (Li, Chen, Qiu, & Yang, 2014). This indicates a
9

positive relationship between medication non-compliance and rehospitalization
rates for individuals with Bipolar Disorder, therefore likely resulting in significant
costs, manpower, and overall distress that perhaps could have been avoidable with
medication compliance.
Developmental disorders. Unlike schizophrenia, a population that has not
received a significant amount of research attention are the individuals who are comorbidly diagnosed with those developmental disabilities and mental illnesses
requiring psychotropic medication. Over 7.5 million individuals in the United
States are affected by a developmental disability (Tan et al., 2015). A
developmental disability is considered to be a group of chronic conditions that
develop from birth to the age of 22 years-old, which can impair physical, cognitive,
communication, behavioral or learning development (Rubin & Crocker, 1989). The
Diagnostic Statistical Manual of Mental Disorders Fifth Edition (DSM-5), refers to
developmental disabilities as Neurodevelopmental Disorders. The DSM-5 states:
The disorders typically manifest early in development, often before the child enters
grade school, and are characterized by developmental deficits that produce
impairments of personal, social, academic, or occupational functioning (p.71,
American Psychiatric Association, 2013).
It has been found that 31-41% of the developmental disability population
suffer from mental illness, therefore resulting in this population having four times
the prevalence rate of mental illness compared to that of the general population
10

(Tan et al., 2015). Another distinction of the developmental disability population in
comparison to the general public is that the individuals in the developmental
disability population often rely on their caregivers to provide them with their
medication. Therefore, this adds another confounding variable to the compliance of
medication, due to the decision-making often being done for the individual by
another person (Tan et al., 2015).
In a study comprised of 3,905 individuals co-morbidly diagnosed with
developmental disability and mental illness who were prescribed psychotropic
medication, it was found that 25.7% (approximately 976 individuals) were noncompliant with their medication (Tan et al., 2015). It was also found that significant
barriers to psychotropic medication non-compliance included being female,
belonging to a minority race, suffering from gastroesophageal reflux disease
(GERD), and enrollment in a capitated health plan (Tan et al., 2015).
Substance use disorder (SUD). It has been found that individuals who
have a co-morbid psychiatric diagnosis(es) and a substance use disorder (SUD) are
found to be significantly less compliant with their medications, in comparison to
those individuals without a SUD (Herbeck et al., 2010). The Substance Abuse and
Mental Health Services Administration reported in 2015 that there are
approximately 20.2 million adults in the U.S. who have experienced, or are living
with a SUD. Of those, 20.2 million, approximately 50.5%, or 10.2 million adults
also suffered from a co-occurring mental illness. With regard to research, there has
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been a significant focus on the relationships between cannabis use and medication
compliance in individuals experiencing their first episode of schizophrenia.
However, despite the numerous studies on this topic, it remains unclear whether
cannabis use has a significant effect on medication non-compliance (Miller et al.,
2009).
To further clarify the relationship between cannabis use and medication
non-compliance with individuals diagnosed with schizophrenia, Miller et al. (2009)
conducted a study in which individuals experiencing their first schizophrenia
episodes were monitored for a 12-month period with both their medication
compliance, as well as their cannabis use. At the conclusion of the study, it was
found that participants who utilized cannabis during the 12-month period, were
found to be significantly less compliant with their medication, compared to
individuals who did not use cannabis during this treatment period (Miller et al.,
2009).
Psychotropic Medication Abuse
Thus far, this paper has focused more on medication non-compliance being
defined as either missing medications, or taking less than the prescribed amount.
However, alternatively, medication non-compliance can also be thought of as
overusing, or abusing the prescribed psychotropic medication. There are a few
medications well-known in the psychiatric community as “drugs of abuse”; these
generally include both stimulants and benzodiazepines (Pierre, 2019). As a result of
12

the common-knowledge of the abuse potential of these medications, they are
considered to be government controlled substances.
However, research highlights the evidence that more frequently noncontrolled substances such as anticholinergics, antidepressants, antipsychotics, and
gabapentinoids are being abused or sold to others, by the individuals to whom they
are prescribed (Pierre, 2019). An anticholinergic, Trihexyphenidyl, has been found
to be used as a form of currency in the prison system due to its popularity, as
inmates reportedly crush this medication and smoke it by combining it with
tobacco (Christensen & Garces, 2006). Trihexyphenidyl has also been reported to
have been consumed with alcohol to increase the effects of both substances,
simultaneously (Pierre, 2019).
During 1966-1998, 21 case reports were published depicting individuals
experiencing psychological and physical dependence to antidepressant medications.
When compared to the millions that were prescribed antidepressants during this
time period, it is not found to be a significant percentage that developed addictions.
However, since 2002, individuals have been reported for non-compliance with the
antidepressant, Bupropion, also commonly sold under the brand name Wellbutrin
and Zyban, in numerous ways such as taking over five times the prescribed dose,
snorting the medication, and most recently, through intravenous injection (Pierre,
2019). In fact, between 2000-2013, more than 975 cases of intentional Bupropion
abuse were reported to the US Poison Control Centers, it was also reported that the
13

numbers of this intentional abuse to the US Poison Control Centers tripling
annually between the years of 2000-2012.
Second generation antipsychotics, also known as, atypical antipsychotics,
have also increased their abuse potential. It has been reported that both Olanzapine
and Quetiapine have been found to be bought, sold, or traded among users for their
stimulating effects, as well as their ability to ease a “come down” from other drugs
(Pierre, 2019). Quetiapine is often used in the prison population for its sedative
properties, and it is found to be used both orally and intranasally and is referred to
as “quell” (Christensen & Garces, 2006).
Gabapentinoids are also a commonly found psychotropic drug of abuse.
These medications are often abused in numerous manners including orally,
intramuscularly, intravenously, rectally, and intranasally (Pierre, 2019). There has
been a significant increase in the street value of these medications since 1997,
resulting in a simultaneous medication non-compliance such that those who are
prescribed this medication are selling it rather than using it, while those who are not
prescribed this medication are found to be abusing it (Pierre, 2019). It should be
noted that a common practice of Bupropion abusers is to first insufflate, or snort,
gabapentinoids, as a method for numbing the nose before snorting the Bupropion
(Christensen & Garces, 2006).

14

Ethnic Diversity and Non-Compliance
Research has shown that there are significant distinctions found when
comparing race and medication non-compliance rates. A study in 2005 illustrated
this difference by comparing the medication compliance of monolingual Hispanics,
bilingual Hispanics, Caucasians, and African Americans (Diaz, Woods, &
Rosenheck, 2005). In this study, medication compliance was accounted for by the
use of a Medication Event Monitoring System cap (MEMS; Diaz, Woods, &
Rosenheck, 2005). The results indicated that of 44 monolingual Hispanics, 23%
were found to be non-compliant, of 25 bilingual Hispanics, 24% were found to be
non-compliant, and of 19 African American participants and 34 Caucasian
participants, 32% and 10%, respectively, were found to be non-compliant (Diaz,
Woods, & Rosenheck, 2005). Therefore, the hypothesis was supported that of those
studied, minority ethnic groups are significantly less compliant with their
prescribed medications than are Caucasians (Diaz, Woods, & Rosenheck, 2005).
A study focusing on medication non-compliance for individuals prescribed
antidepressants found that age and race were the strongest predictor factors in noncompliance (Rivero-Santana, Perestelo-Perez, Perez-Ramos, Serrano-Aguilar, &
De Los Cuevas, 2013). It was found that the increased age of the participants
significantly enhanced the likelihood for medication compliance. It was also found
that with regard to race, Caucasian participants had significantly higher results of
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medication compliance, and the Hispanic population within the sample had the
lowest rates of compliance (Rivero-Santana et al., 2013).
Lanouette, Folson, Sciolla, and Jeste (2009) found that in multiple studies,
Latino individuals consistently exhibited significantly greater medication noncompliance in comparison with their Euro-American counterparts. They also
reported that significant barriers to medication compliance for this population
included, being a monolingual Spanish speaker, low socioeconomic status, and
lacking health insurance. Ralat, Depp, and Bernal (2018) further investigated the
low medication compliance rates in the Latino mental health community. After
completing extensive interviews with 22 participants diagnosed with Bipolar
Disorder I/II, five significant reasons for non-compliance were brought to light;
stigma about the psychiatric condition, patient-related reasons, medication-related
reasons, poor support from family members, and provider relationship factors
(Ralat et al., 2018).
The Substance Abuse and Mental Health Services Administration reported
in 2015 that there were significant differences in mental health service use in
comparing ethnicities. They reported that African American and Hispanic
Americans were half as likely to use mental health services compared to Caucasian
Americans. Furthermore, it was found that Asian Americans were only one third as
likely to use mental health services as Caucasian Americans.

16

Geriatric Population: Aging Effect and Non-Compliance
Another population that is often overlooked when researching and
discussing medication non-compliance is the geriatric population, which is a
significant oversight when it is recognized by previous studies that 20-80% of
geriatric patients prescribed antidepressant medication fail to adhere to their
medication within one month of the prescription being filled (Bosworth, Voils,
Potter, & Steffens, 2008). A consideration that needs to be made when studying
geriatric psychotropic medication compliance is the real concern of the effect of
dementia on medication compliance.
In 2018, it was found that 5.6 million individuals age 65 or older had been
diagnosed with Alzheimer’s dementia in the United States, with a predicted
increase to approximately 14 million individuals, by 2050 (Alzheimer’s Cares
Resource Center, 2019). Dementia has been found to cause cognitive deficits in
older adults that affect their ability to organize, plan, and perform medication
management tasks (Smith et al., 2017).
A study completed on a geriatric population was performed analyzing the
treatment attitudes and beliefs, in association with race and gender difference, in
compliance with antidepressant medications (Burnett-Zeigler et al., 2013). The
study was comprised of 186 African-American and Caucasian participants aged 60
years or older, diagnosed with depression, as indicated by a score of 5 or higher on
the Geriatric Depression Scale, and provided with recommendation for
17

antidepressant medication (Burnett-Zeigler et al., 2013). The subjects were assessed
at the initial baseline interview and again at the four- month follow-up session.
Medication compliance was measured through the use of the Brief Medication
Questionnaire (BMQ) validated compliance question.
For this study, medication compliance was defined as missing 0-1 doses
within a one-week period. The participants also completed the Patients Attitudes
Toward and Ratings of Care for Depression, and a modified version of the Stigma
Scale for Receiving Psychological Help. After the four-month follow-up period, the
results were analyzed, and it was found that both African American men and
women had significantly more concerns with regard to the antidepressant treatment,
and significantly less understanding about the treatment than the Caucasian women
in the study. It was also found that African American men experienced significantly
more negative views of healthcare providers than African American or Caucasian
women. In actual medication compliance, it was found that Caucasian women were
significantly more adherent to their medication regime than were the African
American women (Burnett-Zeigler et al., 2013). Therefore, it is suggested that both
African American men and women are more likely to be non-compliant with their
medication in comparison with Caucasian women.
Another factor to consider when analyzing medication non-compliance with
geriatric populations is the ability to properly read and understand the prescription
labels printed on their medication bottles. Moisan, Gaudet, Gregoire, and
18

Bouchard, (2002) conducted a study comprised of 325 participants aged 65 or older
living in Quebec City, Canada. These individuals were asked to read three
prescription labels out-loud to the evaluator of the study, and were then assessed as
to their understanding of the prescription label instructions. It was found that of the
325 participants aged 65 or older, 126 respondents (38.8%) were unable to read all
of the labels, and 218 (67.1%) respondents did not fully understand the prescription
instructions (Moisan et al., 2002).
Therefore, over two-thirds of this sample population was unable to fully
understand the medical instructions accompanying their prescriptions. These
findings would suggest that the ability of individuals age 65 or older to properly
comply with their medications would be quite hindered if they could not either
read, or fully understand, either the dosage or times to take said medication. The
study found that of the 325 participants, 153 (47.1%) were medication noncompliant.
Factors Contributing to Non-Compliance
Participants in medication non-compliance studies have attributed their
non-adherent behavior to reasons such as forgetting (Bulloch & Patten, 2010),
experiencing adverse side-effects from the medication (Breen & Thornhill, 1998;
Chandra et al., 2014),), financial issues/ limitations (Breen & Thornhill, 1998;
Chandra et al., 2014), the amount of participation the patients have with their
provider (Mahone, 2004; Nageotte et al., 1997), perceived ineffectiveness of the
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medication (Breen & Thornhill, 1998), feeling embarrassed about needing
medication (Rummel-Kluge, Shuster, Peters, & Kissling, 2008), and discontinuing
the medication because of feeling better (Bulloch & Patten, 2010).
Medication and adverse side-effects. Another significant factor found in
medication non-compliance is the individual’s decision that the adverse side effects
from the medication outweigh the benefits that would result from complying with
medication (Breen & Thornhill, 1998). Categorically, the seven groups of
medications which are often considered to be the most common prescribed to
individuals suffering from mental illness include: antidepressants, mood stabilizers,
antipsychotics, anxiolytics, sedative-hypnotics, antiepileptic’s, and sedating
antihistamines (Bennet et al., 2018; Bulloch & Patten, 2010; Lupattelli et al., 2015;
Nageotte et al., 1997; Tan et al., 2015). Breen and Thornhill’s (1998) research
found that all psychotropic medications are able to induce at least one or more
significant side effect for the user. In fact, each category of psychotropic
medication listed above maintains its own set of adverse side effects that may result
in medication non-compliance.
Antipsychotic medications have long interested researchers because of their
significant side effects on individuals. The extrapyramidal syndrome that often
occurs with antipsychotic medication use is comprised of many debilitating
symptoms including Parkinsonian muscle rigidity, drooling, tremors, slowness of
movement, and tardive dyskinesia (Breen & Thornhill, 1998). Other adverse side
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effects often found correlated with use of antipsychotic medication include:
Akathisia, extremely uncomfortable restlessness, dysphoria, or sedation, which can
all negatively impact the individual’s ability to work, obtain an education, or drive
(Breen & Thornhill, 1998). The development of second generation antipsychotics,
otherwise known as atypical antipsychotics, allow individuals more efficacious
treatment with less adverse side effects. Nonetheless and despite these changes,
there is still a significant amount of medication non-compliance within the
population prescribed these medications (Velligan, Lam, Ereshefky, & Miller,
2003).
A common atypical antipsychotic adverse side effect is significant weight
gain, which is likely to result in more medication non-compliance amongst those
who are experiencing these side effects. (Verma, Rao, & Verma, 2015). Adverse
side effects are not always acute, and at times, may lead to presentations that are
more chronic. One of example of this is the complications associated with tardive
dyskinesia.
Atypical antipsychotic use has also been positively correlated with the
production of Type 2 Diabetes Mellitus in children and adolescents who are being
treated for psychiatric disorders (Lee et al, 2018). A Korean study compared
1,092,019 children ages 2-19 who were prescribed antipsychotic medications
compared to non-medicated controls. After four years of data collection, it was
found that Korean children who were prescribed atypical antipsychotics were
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significantly more likely to develop Type 2 Diabetes Mellitus than controls. It is
interesting to note that the primary diagnosis for atypical antipsychotic medication
use was Anxiety, followed by Depression. It is further noted that, Bipolar Disorder
and Schizophrenia were found to be the least diagnosed disorders for antipsychotic
medication use in this sample (Lee et al., 2018).
Usher, Park, and Foster’s (2012) study conducted in Australia, performed
in-depth interviews with eight participants, age 18 to 60, who experienced
significant weight gain as a result of taking atypical antipsychotic medications after
being diagnosed with schizophrenia. The results of these interviews indicated that
these individuals gained between 10 to 50 kilograms, or 22 to 110 pounds,
respectively, after beginning to take their atypical antipsychotic medications. All of
the participants in this study reported either taking themselves off of the
medication, having their doctor take them off of the medication, or seriously
considering no longer taking the medication as a result of the weight gain side
effect. The participants also discussed the lowered quality of life, despite a
significant decrease in their schizophrenic symptoms, they experienced due to
feeling shame as a result of the weight gain (Usher et al., 2012).
Selective serotonin reuptake inhibitors (SSRI’s) are a frequently prescribed
antidepressant. Common adverse side-effects related to SSRIs include nausea,
which can develop into significant vomiting and diarrhea (Breen & Thornhill,
1998). Another common adverse side effect of taking antidepressant medication is
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sexual dysfunction, including both loss of libido, and an increase in premature
ejaculation (Hudson, Fortney, Pyne, Lu, & Mittal, 2015). Sleep changes such as
insomnia or hypersomnia are also side effects of antidepressant medication, as well
as headache, dry mouth, dizziness, and vision change (Hudson et al., 2015).
Antidepressant medication is also found to be used to treat disorders other than
depression, such as anxiety disorders, eating disorders, sleeping disorders, social
phobia, panic disorders, urinary incontinence, and neuropathic pain (Gardarsdottir,
Heerdink, Djik, & Egberts, 2007).
Anxiolytics (i.e., Xanax, Ativan, Klonopin, and Valium) are commonly
prescribed in the mental health community to treat anxiety-based disorders. Side
effects of anxiolytics include drowsiness, sedation, postural instability, visuomotor
impairment and memory impairment (Chen et al., 2017). Furthermore, anxiolytics
have a high tendency for potential abuse, dependence, as well as tolerance and
withdrawals symptoms when used for long-term treatment (Tiwari, Souza, &
Muller, 2009). This highlights the area of non-compliance such that, and unlike
with antidepressants and antipsychotics, the individuals taking anxiolytics are more
likely to overtake or abuse their medication. Additionally, it is not uncommon for
an individual to take these medications sparingly, in an effort to self-regulate the
potential for substance dependence.
As the concern of adverse side effects continues to be correlated with noncompliance to medication, research has continued to work to understand the
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significance of this barrier so that it may be properly addressed in the future. A
study performed in 2008 in the United Kingdom focused on the non-compliance
rates of bipolar disorder individuals to further understand the salience of this
phenomenon (Clatworthy et al., 2009).
In this study, participants were recruited through the use of an
advertisement in the Manic Depression Fellowship newsletter (Clatworthy et al.,
2009). 259 participants requested to join the study and were provided with booklets
containing the Beliefs about Medication Questionnaire, the Medication Adherence
Report Scale, the Beck Depression Inventory, and the Altman Self-Rating Mania
Scale (Clatworthy et al., 2009). All the individuals (N=223) completed and
returned the questionnaire booklet and it was found that 90% of the responding
individuals had experienced one or more hospitalizations and 30% of responders
were considered to be low adherers to their medication (Clatworthy et al., 2009). It
was also found that the individuals who were prescribed lithium had a stronger
likelihood of being medication adherent when compared to those who were not
prescribed it (Clatworthy et al., 2009). The results also supported the hypothesis
that individuals who have a lower perceived need for treatment would also have a
lower medication adherence rate (Clatworthy et al., 2009).
Forgetting. Another significant barrier to medication compliance has found
to be the act of forgetting. A study measuring the medication non-compliance of
6,201 Canadian citizens prescribed psychotropic medications found that the most
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common reason for non-compliance across the five medication classes studied, was
the forgetting to take one’s medication (Bulloch & Patten, 2010). The study also
found that the non-compliance rates varied depending on the class of the
medication: the non-compliance rate for individuals taking antipsychotic
medications was 34.6%, whereas the non-compliance rate for those taking
antidepressants was 45.9% (Bulloch & Patten, 2010). Similarly, to the
antipsychotic class, individuals taking sedative-hypnotics and anxiolytics reported
non-compliance rates of 34.7% and 38.1% respectively, whereas the individuals
taking mood stabilizers reported a non-compliance rate of 44.9% (Bulloch &
Patten, 2010).
Stigma and non-compliance. Another reason that individuals report noncompliance to their medications is due to experiencing, or anticipating
experiencing, stigma from others due to their mental health conditions. A study
completed by Chaudhry, Kumar, and Mishra (2016) revealed that out of 100
participants, aged 18-65, who were identified as non-compliant with their
medications, 40% cited one of the factors involved in their non-compliance to be
the stigma perceived or felt by others due to their mental illness.
A study based in Hong Kong found that stigma was a significant factor in
medication non-compliance for Chinese individuals. Lee, Chiu, Tsang, Chui, and
Kleinman (2006) conducted a study comparing the stigmatization of a
schizophrenia diagnosis and subsequent treatment, with a diagnosis of Diabetes
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Mellitus and subsequent treatment. This study was comprised of 320 participants
diagnosed with schizophrenia and 160 participants diagnosed with diabetes
mellitus, and the individuals were asked to complete surveys which measured the
amount of stigma they received as a result of their illness and how this stigma
affected their behaviors with regard to their illness.
It was found that 48% of the participants diagnosed with schizophrenia felt
significantly more stigmatized due to their diagnosis when compared to those with
diabetes. This felt-stigmatization resulted in those participants reported suffering
workplace difficulties, family rejection, and treatment non-compliance (Lee et al.,
2006).
Decreasing Non-Compliance
As medication non-compliance is a salient global issue, there are many
researchers who are working towards solving this seemingly endless problem. One
of the methods considered is the use of technology to aid in reminding individuals
to take their medication. A 2013 study analyzed the efficacy of short messaging
service (SMS) text reminders to measure the compliance of medication compliance
with an intervention group, and comparing the findings to a control group that
received no such reminders (Huang et al., 2013)
This study was comprised of 1198 participants who had been recruited by
pharmacists from three medical centers. The experimental group was comprised of
763 participants who received the SMS reminders daily for seven days, and 435
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participants were placed in the control group who did not receive SMS reminders.
On the eighth day, the participants completed a follow-up interview phone call in
which they completed a survey to verify their medication compliance. It was found
that the participants who received the reminder messages were significantly more
likely to be medication compliant when compared to the control group. In fact, the
individuals in the intervention group were 3.2 times as likely to take their
medication on time, and 2.2 times less likely to miss a dose than those in the
control group (Huang et al., 2013).
Another salient factor of mental health medication compliance is the
relationship between the individual and their medical provider. This notion became
popular after Sigmund Freud declared the importance of connecting the individual
to the treatment as well as to the physician (McCabe et al., 2012). Although this
statement was originally made with regard to psychotherapy, it has since
generalized to psychiatry and pharmacological treatment in the mental health field.
McCabe et al. (2012) conducted a study in which 134 clinicians were paired
with 507 of their patients and asked to rate their therapeutic relationship as well as
predict the medicine compliance of the individual. It was found that the better the
patient perceived the therapeutic relationship between themselves and their
clinician, the more likely they were to be medication compliant (McCabe et al.,
2012).
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A study conducted by Hamrin and Iennaco (2017), explored the efficacy of
using Motivational Interviewing to increase psychotropic medication compliance in
adolescents. This study was comprised of 41 adolescents ranging in age from 1218, recruited from a university mental health center. The study utilized the
Medication Electronic Monitoring System (MEMS) as the primary measure of
medication compliance and the Drug Attitude Inventory (DAI) was used as a
secondary measure. All participants provided a 30-day baseline MEMS and DAI
measurement at the beginning of the study. Each participant received two
Motivational Interviewing sessions within their standardized medication treatment
appointments with their provider. At least 30 days following their second
Motivation Interviewing session, each participants MEMS and DAI were remeasured.
Results of the study found that, at baseline, 43.9% of participants were
taking their medications between 80-100% of the time. However, after the
Motivational Interviewing intervention, 70.7% of participants were taking their
medications 80-100% of the time. There was also found to be a significantly higher
DAI score after the Motivational Interviewing sessions than at baseline (Hamrin &
Iennco, 2017). This study indicates the salient effect that can occur on psychotropic
medication compliance through the use of non-invasive measures such as providing
motivational interviewing at medication appointments.
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Rationale for Purposed Study
Psychotropic medication non-compliance is a global issue that negatively
influences the lives of millions of individuals every year. Non-compliance with
psychotropic medications also has significant economic consequences, as between
100-300 billion dollars are annually spent on avoidable costs including;
rehospitalization, unemployment, absence from work, and premature mortality
(Semahegn et al., 2018). There has previously been substantial research conducted
on psychotropic medication non-compliance in specific populations, such as
individuals diagnosed with Schizophrenia and Bipolar Disorder. However, there is
a noteworthy gap in the literature with regard to general outpatient community
mental health populations.
The American Psychological Association reported that approximately 25%
of all U.S. adults have a mental illness, and that almost 50% of all U.S. adults will
develop a mental illness during their lifetime (American Psychological Association,
2019). This is significantly greater than the prevalence of individuals suffering
from schizophrenia in the U.S. at 0.3%- 0.7%, and greater than the prevalence of
individuals in the U.S. suffering from Bipolar Disorder I at 0.6% and Bipolar
Disorder II at 0.8% (American Psychiatric Association, 2013).
Therefore, there has been drastically more research on medication noncompliance for disorders that make up less than 3% of the population, and very
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little research on the medication compliance of the general outpatient mental health
population, which is nearly half of the population of adults in the United States.
Data obtained from this proposed research could have potentially
meaningful implications for both the individual and the medication provider. By
identifying the factors preventing psychotropic medication non-compliance in the
general mental health outpatient population, the barriers to fully complying with
medication can begin to be overcome. This would benefit the individual in
receiving the full efficacy of the treatment effects of the medication, which would
in turn benefit the provider.
Furthermore, more studies conducted regarding factors contributing to
medication non-compliance in the general mental health population could result in
preventing billions of dollars being spent annually on rehospitalization,
unemployment due to mental health problems, absence from work, and premature
death. Additionally, mental illness is significantly associated with chronic diseases
such as cardiovascular disease, obesity, asthma, epilepsy, and cancer (American
Psychological Association, 2019). In fact, the National Association of State Mental
Health Program Directors Council reported in 2006, adults in the U.S. living with
serious mental illness, on average, die 25 years earlier than others, largely due to
medical conditions that are treatable! Therefore, by creating more medication
compliance, through the identification of factors that preclude compliance in the
general mental health outpatient population, this study also has the potential to
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contribute to the growing information in the medical field with regard to the
prevention of such chronic diseases, and premature death in the general population.
Goals and Objectives
Review of the literature has suggested that medication non-compliance in
the general mental health population is a significant problem, and that it negatively
impacts not only the health of individuals, but also significantly impacts our
economy. It is also suggested that medication non-compliance is the result of
multiple factors, including; Forgetting, Adverse medication Side Effects, Religious
Reasons, Inconvenience, History of Addiction, Instructions too Complicated, and
Unsure if Medications are Working.
The goal of this study is to identify which factors are the most salient in
precluding medication compliance amongst the general mental health outpatient
population, in the hopes that preventative measures can be developed to assuage
these barriers to compliance.
Therefore, identifying (1) the factors that impede psychotropic medication
compliance, and, (2) if individuals prescribed antipsychotics have significantly less
medication compliance than others in the general mental health population, are
relevant objectives to this study. Obtaining this information will provide health care
workers in the mental health field a basis from which to begin developing programs
and practices to overcome these compliance obstacles. As there is currently a
significant paucity of information as to the factors that inhibit medication
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compliance in the general outpatient mental health population, this study could
provide a deeper understanding as to interventions that need to be implemented to
make medication compliance accessible to everyone. The purpose of the current
study is to expand the research of psychotropic medication non-compliance to that
of the general outpatient mental health population, rather than focusing on specific
disorders such as Schizophrenia and Bipolar Disorder. This will increase our
understanding of the challenges that the general population faces with regard to
fully complying with their medications and allow future research to expand upon
interventions that will increase psychotropic medication compliance in the general
mental health outpatient population.
Aims and Hypotheses
Based on the reviewed literature relating to this project, the following hypotheses
will be tested:
1. The most salient factor of non-compliance will be due to Forgetting,
followed by adverse side effects, as a result of the medication.
2. Participants who are prescribed antipsychotics will report significantly
more medication non-compliance than individuals who are prescribed
antidepressants, anxiolytics, anti-epileptics, sedative-hypnotics, or
sedating antihistamines.
3. As the number of factors that influence medication compliance
increases, participants’ non-compliance should likewise increase.
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Method
Procedure
This study was approved by the Florida Institute of Technology Institutional
Review Board (IRB) prior to participant recruitment. Participants were recruited
from within two local, Circles of Care Inc., community mental health clinics.
Circles of Care, Inc. is a non-profit mental health-based program comprised of
inpatient, crisis services, and outpatient mental health care services through its
hospital-based and State and County contracted programs. Circles of Care has 52
licensed hospital beds, 50 state licensed adult crisis stabilization beds, 78 licensed
residential and treatment beds, 18 licensed chemical dependency detoxification
beds, 12 licensed chemical dependency intensive residential treatment beds, 16
children's crisis stabilization beds as well as a complete continuum of outpatient
care to provide services to residents of the Brevard County community. Permission
was granted to the authors to survey and collect data from the clients at their two
local outpatient clinics. Data was collected via a self-report survey. Participants
were provided with a paper copy of the informed consent and survey as part of their
intake packet for treatment (see Appendix B.).
Patient’s responses were kept confidential and they were not asked to
identify themselves on the questionnaire. The informed consents were kept in a
separate file from the surveys that were collected. This allowed there to be no
matching of informed consent with survey data and maintain the confidentiality of
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the participant. Inclusion criteria for the study consisted of a: (1) diagnosis of a
psychiatric disorder, (2) prescription of a psychotropic medication, (3) concurrent
illicit drug use and, (4) be between the age of 18-90.
Outcome Measures
The survey utilized was created specifically for use within this study. The
survey requested basic demographic information such as age, gender, ethnicity,
employment status, sexual orientation, and education level. It also asked
participants to identify which of the psychotropic medications, if any, provided on
the survey, they are prescribed, with an option to write in medications if they are
not listed on the survey. Compliance with medication was evaluated using a Likert
scale.
The Likert scales provided a measure of the participant’s compliance with
their prescribed dosage guidelines and their likelihood of terminating medication
use without consulting their prescribing doctor. An example of one of the Likert
Scale questions on the survey is as follows:
Of the medications circled above, and is prescribed daily, (Please write in
your medication) ________________, How often do you take half, or less
than half of the recommended dosage of this medication?
The participants were then provided a Likert Scale from 1 (Never) to 4
(Always). If medication non-compliance was identified, as evidenced by choosing;
3 (Most of the Time) or 4 (Always), patients were then asked to identify the
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factor(s) that function as a barrier to their medication compliance. Additionally, the
questionnaire utilized questions from the Drug Use Screening Inventory-Revised
adult survey (DUSI-R).
The DUSI-R is a self-report questionnaire used to examine the severity of
problems in 10 domains, one of them being substance use. For the purpose of this
study, only the component of the DUSI-R, which is used to screen for involvement
with drugs, was utilized. This measure allowed the researchers to analyze potential
associations between rate of medication non-compliance and frequency of drug use.
The participants were asked to identify each substance used within the past year,
and how many times used per month (see Appendix A.).
Data Analysis
The questionnaire utilized four types of questions to measure rates of
participant compliance and non-compliance to medication. Two types of questions
asked participants to rate non-compliance on a Likert scale while the other two
asked for the same ratings pertaining to compliance. To obtain an overall noncompliance score, response to questions pertaining to compliance were reverse
coded to reflect a rate of non-compliance. Then, ratings across all questions were
summed to obtain an overall non-compliance score for each participant.
To test the first hypothesis a multiple regression was performed to identify
if the factors of Forgetting followed by Adverse Side Effects were predictive ones.
The goal was to identify which, if any, were significant as the most salient factors
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that preclude medication non-compliance. A simple linear regression was then
conducted on the conditions of compliance including: Terminating medication use
without first consulting their physician, how often the participant fully complies
with the dosage guidelines on their prescription, how often does the participant take
half or less than half of their prescribed medication, and how often is each
medication taken on a daily basis. The conditions of compliance were then
compared with the non-compliance factors to identify if individual non-compliance
factors significantly predicted conditions of non-compliance.
To test the second hypothesis, an independent samples t-test was run to
identify if individuals who are prescribed antipsychotics are significantly less
compliant with their medication regimen, than individuals who are prescribed
antidepressants, anti-epileptics, sedative hypnotics, sedating antihistamines, or
anxiolytics.
Finally, to test the last hypothesis, a linear regression was conducted to
identify if the number of precluding factors of medication non-compliance
increased, would the overall medication non-compliance significantly increase as
well.
Results
Participants
A total of 237 participants volunteered to take the survey. Of this total, 42
cases were removed, due to missing values in regard to compliance data. As
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compliance behavior was the primary variable of interest, participants who did not
disclose this information were removed from the study as well. Therefore, 195
cases remained and were reviewed for this study.
Among the remaining 195 participants, 31.8% male (n=62) and 68.2% were
female (n=133). 34% were between the ages of 41-55 (n=69), 29% were between
the ages of 26-40 (n=55), 18% were between the ages of 56-65 (n=34), 8% were
between the ages of 66-74 (n=15), 5% were between the ages of 18-25 (n=9), and
3% were 75 and above (n=6).
81% of participants indicated a heterosexual orientation (n=156). 8%
indicated that they were bisexual (n=16), 8% preferred not to report (n=16), and 2%
reported a homosexual orientation (n=4).
The participants were 82.6% Caucasian (n=161), 8.2% African
American/Caribbean (n=16), 4.2% Hispanic (n= 8), 1.5% Asian (n=3), 2%
American Indian or Native American (n=4), and 1.5% selected other (3).
10.9% of the participants reported having a bachelor’s degree (n=21), 4.7%
of participants reported having a master’s degree (n=10), 20.3% of participants
reported having an associate’s degree (n= 39), 8.8% attended a trade school (n=18),
43.2% of participants reported having a high school diploma or GED (n=84), and
12% indicated that they did not receive a high school diploma or obtain a GED
(n=23).
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12% of the participants reported working Full-Time (n=29), 10% of the
participants reported working Part-Time (n=24), and 58% of the participants
reported being Unemployed (n=138).
Of the participants who chose to respond, 62% indicated that they had been
previously hospitalized (n=121) while 38% reported no history of hospitalization
(n=74).
Statistical Analysis
Most Salient Factor. A multiple linear regression was calculated to predict
medication non-compliance based on Forgetting, Adverse Side Effects, Unsure if
Medications are Working, Inconvenience, Instructions too Complicated, History of
Addiction, Religious Reasons, and Financial Reasons. No significant regression
equation was found F (8,89) = .90, p= .52 with an R2 of .075.
Participant’s medication non-compliance increased as being 0.16 times
more likely to be medication non-compliant if they indicated Forgetting as a factor,
and 0.29 times more likely to be non-compliant if they indicated Adverse Side
Effects as a factor. On the contrary, participant’s medication non-compliance
decreased 0.25 times if they indicated Financial Reasons as a factor, and 0.04 times
if they indicated Religious Reasons as a factor. History of Addiction as a factor
decreased medication non-compliance by 0.01 times, whereas Inconvenience
decreased medication non-compliance 0.19, Instructions too Complicated
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decreased medication non-compliance by 0.29 times, and Unsure if Medications are
Working decreased medication non-compliance by 0.004 times.
None of the predictors including Forgetting, Financial Reasons, Adverse
Side Effects, Unsure if Medications are Working, Inconvenience, Instructions too
Complicated, History of Addiction, or Religious Reasons significantly predicted
medication non-compliance. However, it should be noted that both Adverse Side
Effects and Forgetting correlated in a positive direction with medication noncompliance, but did not result in a significant finding.
Medication Termination. A simple linear regression was calculated to
predict medication non-compliance related to participants who completely stop
using their medication without first consulting their physician based on
experiencing adverse side effects. A significant regression result was found F
(8,63) = 3.46, p<.002, with an R2 of 0.31.
This supported the hypothesis in identifying that the experience of adverse
side effects significantly impacted the compliance rate of participant medication
usage. Participants predicted medication non-compliance due to stop taking their
medication without first consulting their physician is equal to 1.34 + 0.88 times
more likely when adverse side effects are indicated. Medication non-compliance
due to terminating medication without consulting a physician increased by 88%
when experiencing adverse side effects from medication.
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Antipsychotics. An independent sample t-test was conducted to compare
medication non-compliance in participants who were prescribed antipsychotic
medications compared to those participants who were not prescribed antipsychotic
medications.
There was not a significant difference between the scores for participants
who were prescribed antipsychotic medications and participants who were not
prescribed antipsychotic medication (M = 0.63, SD= 0.49; M=0.5, SD = 0.58;
respectively).
Number of Factors. A simple linear regression was calculated to predict
medication non-compliance based on the number of factors that influence
medication non-compliance. A significant regression was not found; F (1,90) =
0.15, p< 0.69, with an R2 of 0.002. However, it was found that medication noncompliance increased 2.4% for each added factor, despite not being a significant
finding.
Discussion
Impact of Study
As previously suggested, it is imperative to conduct further research to
better understand the factors that preclude medication compliance in the general
mental health outpatient population. As it is estimated that 50% of US adults will
experience mental illness in their lifetime (American Psychological Association,
2019) promoting information that will improve medication compliance throughout
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the nation is of great importance. Identifying the factors that preclude medication
compliance is of paramount importance as it is only through isolating the obstacles
that compensatory measures to overcome can be enacted. This problem of
medication non-compliance affects individuals regardless of age (Bosworth, Voils,
Potter, & Steffens, 2008), ethnicity (Diz, Woods, & Rosenhack, 2005), or
neurological development (Tan et al., 2015).
The Agency for Healthcare Research and Quality (2009) reported that
Mood Disorders are the 3rd most common cause of hospitalizations for US
individual aged 18-44 years old. Supporting this statement, Sullivan et al. (1995),
identified that medication non-compliance amongst mental health patients, as being
the most frequent reason for rehospitalization in a mental health facility. It should
be noted that rehospitalization contributes to significant distress on the patient, their
family, and the mental health treatment provider. Furthermore, the impact of
medication non-compliance does not only negatively impact the patients and the
mental health care providers, it also has a significant impact on the US economy.
Iuga and McGuire (2014) reported that an estimated 100-300 billion dollars
are annually attributed to medication non-compliance in the United States. The
National Association of State Mental Health Program Directors Council (2006)
reported that adults in the U.S. living with serious mental illness, on average, die 25
years earlier than others; yet another significant finding reported that medication
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non-compliance is also attributed to increased mortality rates and decreased quality
of life.
Therefore, identifying the most salient factors that contribute to medication
non-compliance will aid to better inform medication providers of potential barriers
to patients fully complying with their medication. As a result, they can develop
preventative programs to alleviate precluding factors to medication compliance.
This study examined the extent that specific factors preclude psychotropic
medication compliance hypothesizing that Forgetting followed by Adverse Side
Effects would be the most salient factors. Although the factors were not found to
be significant, they did support the hypothesis in reporting that Adverse Side
Effects followed by Forgetting were the most salient factors that precluded
medication compliance. It is likely that the small sample size of the study had an
impact on the significance level. It should also be recognized that the survey
utilized was created for this study and therefore the questions may have not been as
clear to participants regarding the salience of the factor that influenced their
medication non-compliance.
Additionally, it was contrary to the hypothesis in that Adverse Side Effects
were more salient in predicting medication non-compliance than Forgetting, rather
than Forgetting being the most salient. These results are contrary to the 2010 study
competed by Bulloch and Patten (2010), which found that out of 6,201 Canadian
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participants, Forgetting was found to be significantly more salient than any other
factor in predicting medication non-compliance, including Adverse Side Effects.
It is possible this occurred because of a smaller sample size, or that with the
increase in access to internet and media related to medication, people may be
relying on electronic reminders and facts rather than selecting forgetting as the
most common influence. Furthermore, method of study may have contributed as
this self-report measure may have influenced participants to be more self-reflective,
or defensive about forgetting, and instead blaming adverse side effects; while the
other study utilized MEMS to obtain a less subjective response.
Further analysis of the data also found that individuals who reported
experiencing Adverse Side Effects as a factor in psychotropic medication noncompliance reported to be significantly more likely to terminate their medication
usage without talking to their doctor than participants who identified any of the
other factors.
This finding is supported by Usher et al. (2012), which looked at eight
Australian participants who reported that experiencing adverse side effect, (e.g.,
weight gain), resulted in all participants prematurely terminating their medication
usage, asking their doctor to terminate their medication, or seriously consider
terminating their medication. Whereas the study in question utilized a significantly
small sample size, it is reassuring to find a commensurate result and further
substantiate the impact of adverse side-effects on non-compliance. Future studies
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focusing identifying which adverse side effects are most salient in predicting
medication on-compliance due to stopping use of the medication without first
consulting a physician would further be useful to both patients and providers.
The second hypothesis indicated that participants who were prescribed
antipsychotic medications were significantly more likely to be medication noncompliant than participants who were prescribed antidepressants, anxiolytics, antiepileptics, sedating antihistamines, or sedative-hypnotics. Semahegn et al. (2018),
reported that individuals diagnosed with major psychiatric disorders tend to be the
most non-compliant with their psychotropic medication. One suspected cause of
this is that individuals who suffer from major psychiatric disorders tend to have
higher impairments to reasoning skills and insight (Semahegn et al., 2018).
Contrary to the hypothesis, no significant difference was found between
individuals prescribed antipsychotic medications in comparison to individuals
prescribed other psychotropic medications. These findings are supported in Bulloch
and Patten’s (2010) study which found that when comparing classes of
psychotropic medication, 45.9% of participants were found to be medication noncompliant taking non-antipsychotics, in comparison to 34.6% of participants found
to be medication non-compliant taking antipsychotics.
It’s difficult to discern the cause for this non-significant result. However, it
is reasonable that once again, the small sample size has proved as a limitation for
this study. It is also feasible that individuals who are prescribed antipsychotics are
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more likely to have their medications monitored or provided to them by caregivers,
family members, or injected monthly by their medication providers. Future studies
would likely benefit from adding a question into the survey regarding if the
individual prescribed antipsychotics takes them daily, or receives monthly
injectable. It would also be beneficial for future studies to identify of the prescribed
medication was time-released or if it was a single-released dose of the medication.
This would be effective in identifying the effect that adverse side effects may be
alleviated through this administration of medication resulting in more compliance
overall. It is also possible that due to having the individuals complete the surveys at
the location of their mental health outpatient care, rather than online, resulted in
participants biasing their answers due to fear of repercussion from their
medications providers. Although it should be noted that it was stipulated in the
informed consent that all survey results would be kept anonymous and there was no
way in which to identify the participants who volunteered for the study.
Lastly, the hypothesis indicated that as number of factors that influence
medication compliance increases, participants’ non-compliance will increase.
Contrary to the hypothesis, no significant result was found. However, it should be
noted that despite the lack of significance, the pattern of increasing medication noncompliance as factors increased was supported in a positive way. In fact, it was
found that for every added factor that precludes medication compliance, there was a
2.4% increase of medication non-compliance in the participants. As one of the
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limitations for the study was the small sample size, it is feasible that had there been
more participants, a significant difference would have been found. It is also
possible that due to wording on the survey that was developed for this study, the
participants did not fully understand that they could identify multiple factors that
resulted in medication non-compliance.
Limitations and Areas for Future Research
Small sample size. As previously discussed, the non-significant results
obtained within this study may be the result of a lack of power due to a smaller
than-desired sample size. A larger sample size may increase the chances of
detecting a true effect within the data. As such, future studies may consider
increasing the sample size to allow for more reliable results with greater power to
detect differences. Obtaining a more globally representative sample among such
a diverse population, may have helped achieve a better ability to generalize
trends of medication non-compliance.
Validity of the Questionnaire. The questionnaire used was adapted for this
study using questions created by the researchers, as well as those adapted from the
Drug Use Screening Inventory-Revised adult survey (DUSI-R). As there was no
pilot study to establish the validity of the questionnaire for evaluating these factors,
there is the potential that the developed questionnaire did not accurately measure
the constructs that were set out to measure within this study. As such, future
research may wish to utilize a questionnaire, whose validity has been confirmed
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and utilized within previous studies. Despite these potential drawbacks in validity
of the questionnaire not being established, the authors of this study chose to
continue in their utilization of this questionnaire, as there were no other available
options of questionnaires developed with established validity measures that
provided the information needed to complete this study.
Additionally, as was mentioned by Hendershot and colleagues (2009), and
Haddad, Brain, and Scott (2014), the use of subjective self-report measures to
identify non-compliance has been shown to have poor validity and a tendency to
underestimate rates of non-compliance within the sample. Therefore, more
objective measures such as a MEMS system, can be utilized within future research
to combat any errors which may occur when using more subjective measures.
However, as has been mentioned, financial limitations, in addition to available
resources for this study prevented using MEMS systems or other more objective
measures. Still, it was believed that viable data could, and was obtained through the
use of the self-report measures of substance use and medication compliance.
Participant Bias. The survey asked participants to disclose information
about sensitive topics such as drug use and medication taking behaviors.
Participants may wish to present themselves, and their behaviors in a more positive
light, by underreporting such behaviors. This may increase error in the research
data and contribute to the difficulty detecting differences between groups.
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Although the experimenters took measures to deter such a bias, such as
informing the participants of confidentiality and anonymity within the informed
consent, participants may still have responded in ways that present themselves in a
more positive light. Future studies may examine the use of other measures, which
minimize the potential for social desirability biased responding.
Conclusion
The study was conducted to address the significant gap in the literature
regarding medication non-compliance in the general mental health outpatient
population. The current study looked to identify which factors were most salient in
precluding medication compliance to inform mental health providers in developing
preventative programs and structures to alleviate these factors for their patients.
The American Psychological Association (2019) reported that nearly 50%
of US adults will experience a mental illness with in their lifetime. This is a salient
issue that has not received nearly enough attention in the manner of research
regarding the medication treatment of these conditions. Research that will increase
the treatment effects for those suffering from mental illness could save the US
economy billions of dollars, as well as alleviate significant pain and suffering from
those afflicted.
Results obtained in this study highlighted the impact that factors such as
experiencing adverse side effects from medication can have on medication
compliance. Previous research indicated that factors such as Forgetting, Adverse
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Side Effects, Religious Reasons, Financial Reasons, History of Addiction,
Inconvenience, Instructions too Complicated, and Unsure if Medications are
Working, have significant impacts on psychotropic medication non-compliance.
As the study did not find support for the antipsychotic medication class to
significantly increase medication non-compliance, it is suggested that future
research focus on antipsychotic medications non-compliance prevention programs
that focus more on Forgetting, Adverse Side Effects, and providing patients with
more tools to alleviate the factors that prevent medication compliance.
With this knowledge, medication providers and patients can work together
to be more informed in preventing medication non-compliance. This salient issue
would benefit from further research to identify more concrete ways in which to
alleviate factors that preclude medication compliance and to provide a stronger
understanding of mental healthcare in the general outpatient community.
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Table 1
Descriptive Statistics of Participant Demographic Information
Variable
Race and Ethnicity
African American/Caribbean
American Indian or Native American
Asian
Caucasian
Other
Hispanic
Age
18-25
26-40
41-55
56-65
66-74
75+
Educational Attainment
No High School Diploma or GED
High school Graduate or GED
Trade School
Associates Degree
Bachelor’s Degree
Master’s Degree
Doctoral Degree
Sex
Male
Female
Sexual Orientation
Heterosexual
Homosexual
Bisexual
Prefer Not to Say
Employment Status
Full-Time
Part-Time
Unemployed
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N

Percent

16
4
3
161
3
8

8.2%
2%
1.5%
82.6%
1.5%
4.2%

9
55
69
34
15
6

5%
29%
34%
18%
8%
3%

23
84
18
39
21
10
0

12%
43%
9%
20%
11%
5%
0

62
133

31.8%
68.2%

156
4
16
16

81%
2%
8%
8%

29
24
138

12%
10%
58%

Appendix A

Demographics
What is your age: (Check One)
18-25

26-40

41- 55

56-65

66-74

75+

What is your gender: (Check One)
Male

Female

Prefer not to say

What is your ethnicity: (Check One)
Caucasian

African American/ Caribbean American

Pacific Islander

Hispanic

Native American/ American Indian Asian

What is your highest level of education: (Check One)
Did not complete High School
Bachelor’s Degree

High School Diploma/ GED

Master’s Degree

Associates

Doctorate

Trade school Certification
What is your current employment status: (Check One)
Full-Time

Part-Time

Unemployed

What is your sexual orientation: (Check One)
Heterosexual

Homosexual

Bisexual

Prefer not to say

What is your marital status: (Check One)
Single/ Never Married

Legally Separated
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Divorced

Widowed

Medical History:
Have you ever been hospitalized overnight due to a psychiatric condition:
(Check One)
Yes

No

Are you currently prescribed any of the following medications? (Circle any/
and all medications that you are currently prescribed)
Antidepressants

Anticonvulsants

Anafranil (Clomipramine)

Neurontin (Gabapentin)

Tofranil (Imipramine)

Klonopin (Clonazepam)

Lexapro (Escitalopram)

Tegretol (Carbamazepine)

Prozac (Fluoxetine

Keppra (Levetiracetam)

Paxil (Paroxetine)

Depakote (Valproic Acid)

Celexa (Citalopram)
Zoloft (Sertraline)

Beta Blocker

Effexor (Venlafaxine)

Ternormin (Atenolol)

Luvox (Fluvoxamine)

Metoprolol (Lopressor)

Desyrel (Trazadone)

Anti-anxiolytics/Sedative

Antipsychotics

BuSpar (Buspirone)

Clozaril (Clozapine)

Ativan (Lorazepam)

Thorazine (Chlorpromazine)

Valium (Diazepam)

Haldol (Haloperidol)

Xanax (Alprazolam)

Seroquel (Quetiapine)

Librium (Chlordiazepoxide)

Geodon (Ziprasidone)
65

Elavil (Amitriptyline)
Abilify (Aripiprazole)
Risperdal (Risperdone)
Zyprexa (Olanzapine)

Other _________________________ (Please write in medication)

If you have more than one prescribed medication, please
answer for each separate medication in section 1, 2, and 3
Section 1:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
_________________, How often do you full comply with the dosage guidelines
on the label?
Please circle your answer below:
1
Never

2
3
Rarely Most of the time

4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
_________________, How often do you full comply with the dosage guidelines
on the label?
Please circle your answer below:
1
Never

2
3
Rarely Most of the time
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4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
_________________, How often do you full comply with the dosage guidelines
on the label?
Please circle your answer below:
1
Never

2
3
Rarely Most of the time

4
Always

Section 2:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take half, or less than half of the
recommended dosage of this medication?
1
Never

2
Rarely

3
Most of the time

4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take half, or less than half of the
recommended dosage of this medication?
1
Never

2
Rarely

3
Most of the time

4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take half, or less than half of the
recommended dosage of this medication?
1
Never

2
Rarely

3
Most of the time

Section 3:
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4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How likely are you to stop taking this medication
completely, without first consulting your prescribing doctor?
1
Never

2
Unlikely

3

4
Likely

Highly Likely

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How likely are you to stop taking this medication
completely, without first consulting your prescribing doctor?
1
Never

2
Unlikely

3
Likely

4
Highly Likely

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How likely are you to stop taking this medication
completely, without first consulting your prescribing doctor?
1
Never

2
Unlikely

3
Likely

4
Highly Likely

Section 4:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take this medication on a daily basis?
1
Once

2
Twice

3
Three or more

4
As needed

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take this medication on a daily basis?
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1
Once

2
Twice

3
Three or more

4
As needed

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take this medication on a daily basis?
1
Once

2
Twice

3
Three or more

4
As needed

Section 5:
Please circle your answer below:
The majority of the time I take the above medication by myself, without assistance
or prompting.
The majority of the time a friend or family member encourages, assists, or reminds
me to take the above medication in some way.

Section 6:
If you answered less than 4 for any of the above questions, what are sometimes
barriers (factors that get in the way) for taking your medication on-time
and/or consistently? (Circle all that apply)
Financial issues/Limitations

Forgetting

Religious Reasons

Side Effects (e.g. impact on appetite, nausea, drowsiness)
History of Addiction

Find it to be an inconvenience

Instructions too complicated

Unsure if medications are working

Other___________________

Section 7:
Of the above circled, Please rank the top three barriers of medication
compliance beginning with the most significant barrier as #1.
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(Please write in answer):
#1 __________________________
#2 __________________________
#3 __________________________

Section 8:
Ordinarily, how many times each month have you used each of the following drugs in
the past year? (NOTE: If you have only used a drug a few times over this past year,
answer “0 times”)
Circle your response:

Alcohol

0 times

Amphetamines/
Stimulants/ “uppers”
Cocaine/Crack

0 times

Prescription diet pills

0 times

Heroin/morphine
/opiates
Methadone

0 times

Prescription pain
killer pills
Barbiturates

0 times

Quaaludes

0 times

Tranquilizer Pills

0 times

LSD/Hallucinogens

0 times

Ecstasy

0 times

PCP

0 times

0 times

0 times

0 times

1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
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3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times

Marijuana

0 times

Glue

0 times

Gasoline or
other fumes
Smoking
Tobacco
Chewing
Tobacco
Anabolic Steroids

0 times
0 times
0 times
0 times

1-2
times
1-2
times
1-2
times
1-2
times
1-2
times
1-2
times

Which drug causes
you the most
problems
Which drug do
you prefer the most
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3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

3-9 times

10-20 times

More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times
More than
20 times

Appendix B

Informed Consent
Please read this consent document carefully before you decide to participate in
this study. The researcher will answer any questions before you sign this form.
Study Titles:
Medication Non-Compliance: Compliance to Psychotropic Medications within
Community Mental Health.
The Impact of Illicit Drug Use on Prescribed Psychotropic Medication Adherence.
Purpose of the Study: The purpose of the current study is to identify factors that
prevent individuals from fully taking their medications as prescribed. One of the
factors that will be investigated further, is the effect of different levels of drug use on
the medication taking behavior of individuals who are prescribed psychotropic
medications. Participants are chosen on a voluntary basis, and this study is offered to
anyone attending outpatient therapy.
Procedures: Participants will be asked to sign this form, as well as complete the short,
attached, survey. The survey will ask for some general demographic information as
well information about current medications, how often the individual takes half or less
than half of the recommended dosage of the medication, and some potential reasons
that may prevent the individual from fully taking the medication as prescribed.
Additionally, individuals will be asked about their drug use. If drug use if identified,
individuals are asked how many times each month have they used, within the past year.
Potential Risks of Participating: Risks to participants are no more than what is
experienced in everyday life.
Potential Benefits of Participating: Participation would allow the medication
providers, as well as mental health professionals, to identify factors that prevent
individuals from taking their medication fully as prescribed. This will help to develop
programs to make medication adherence easier for the participants, resulting effective
treatment and improved outcomes for patients.
Confidentiality: All information will be kept completely confidential. After it is
collected, the informed consent form will be kept separate from the survey form so
there will be no way to match a name to the survey and ensure the information
provided cannot be connected to the individual. Instead of using any identifying
information on the survey, responses will be assigned a code number. The list
connecting your name to this number will be kept in a locked file in the Florida
Institute of Technology Psychology Department. Your name will not be used in any
report. The only individuals who will have access to your responses are the principal
investigators and their advisor. When the study is completed and the data has been
analyzed, the data will be destroyed.
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Voluntary participation:
Your participation in this study is completely voluntary. There is no penalty for not
participating. If you wish to not participate, this will not impact your ability to receive
your prescribed medications. You may also refuse to answer any of the questions we
ask you.
Right to withdraw from the study:
You have the right to withdraw from the study at any time without consequence.
Whom to contact if you have questions about the study:
Emily E. DePetro MS, Principle Investigator
150 West University Blvd.
Melbourne, FL 32901
Email: edepetro2016@my.fit.edu
Lauren N. Stroker MS, BCBA, Principle Investigator
150 West University Blvd.
Melbourne, FL 32901
Email: Lstroker2014@my.fit.edu
Whom to contact about your rights as a research participant in the study:
Dr. Lisa Steelman, IRB Chairperson
150 West University Blvd.
Melbourne, FL 32901
Email: lsteelma@fit.edu Phone: 321.674.8104
Agreement:
I have read the procedure described above. I voluntarily agree to participate in the
procedure and I have received a copy of this description.
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